BioMerieuxLTS:0RUG -0.82%71 OCF Margin % is 23.24% as of Dec. 2025, which is 43% above its 10-year median of 16.24. GuruFocus rates LTS:0RUG with a GF Score™ of 71/100 and a GF Value™ of €109.89 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BioMerieux ranks better than 76.47% on this metric.
The historical rank and industry rank for BioMerieux's OCF Margin % or its related term are showing as below:
LTS:0RUG'
s OCF Margin % Range Over the Past 10 Years
Min: 12.12 Med: 16.24 Max: 24.43
Current: 19.37
During the past 13 years, the highest OCF Margin % of BioMerieux was 24.43%. The lowest was 12.12%. And the median was 16.24%.
LTS:0RUG's OCF Margin % is ranked better than 76.47% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755
vs LTS:0RUG: 19.37
BioMerieux OCF Margin % Related Terms
BioMerieux OCF Margin % Historical Data
* Premium members only.
The historical data trend for BioMerieux's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RUG vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, BioMerieux's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's OCF Margin % distribution charts can be found below:
* The bar in red indicates where BioMerieux's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMerieux (LTS:0RUG) has a OCF Margin % of 23.24% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioMerieux and its competitors. This is 43% above median its historical median of 16.24. Over the past decade, BioMerieux's OCF Margin % has ranged from 12.12 to 24.43. According to the industry distribution chart, BioMerieux ranks #48 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 23.5%.
Is BioMerieux's OCF Margin % too high?
BioMerieux's current OCF Margin % of 23.24% is 43% above median its 10-year median of 16.24. Over the past 10 years, this metric has ranged from a low of 12.12 to a high of 24.43. The Medical Diagnostics & Research industry median OCF Margin % is 4.76. BioMerieux's value of 23.24% is 388.7% above this industry median. Based on the distribution chart, BioMerieux ranks #48 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BioMerieux has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #48 out of 204 companies for OCF Margin %. This places BioMerieux in the top 24% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.76. BioMerieux's value of 23.24% is 388.7% above this benchmark. Historically, BioMerieux's own OCF Margin % has ranged from 12.12 to 24.43 over the past decade. While the company's 10-year median is 16.24 vs. the industry median of 4.76, BioMerieux has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMerieux's current OCF Margin % of 23.24% is 388.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BioMerieux and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMerieux's current OCF Margin % is 23.24%, which is 43% above median its own 10-year median of 16.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (LTS:0RUG) is currently considered Significantly Undervalued. The stock's GF Value™ is €109.89, compared to a current price of €66.55 — trading 39.4% below its estimated fair value. The current OCF Margin % is 23.24%, which is 43% above median its 10-year median of 16.24 and 388.7% above the Medical Diagnostics & Research industry median of 4.76. BioMerieux's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BioMerieux (LTS:0RUG), the current OCF Margin % is 23.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (LTS:0RUG) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €66.55 is trading 39.4% below its estimated GF Value™ of €109.89.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for LTS:0RUG:
OCF Margin %: 23.24% (43% above median its 10-year median of 16.24)
GF Value™: €109.89 vs. price of €66.55 (39.4% below fair value)
Industry Position: 388.7% above the Medical Diagnostics & Research median (#48 of 204)
No single metric tells the full story. See the LTS:0RUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
71GF Score
Get the complete analysis for LTS:0RUG
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RUG has been successfully added to your 
